Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01472939 · ClinicalTrials.gov registry record · Phase 2
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
A Phase 2 study of Gastroesophageal Reflux Disease, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT01472939 is a Phase 2 study of Gastroesophageal Reflux Disease that has completed, run by Shire. The registered enrollment target is 480 participants, above the 328-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT01472939, a Phase 2 study of Gastroesophageal Reflux Disease, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this study is to establish a dose-related effect of a selective 5-HT4 receptor agonist compared to placebo on residual symptoms (regurgitation with or without heartburn) in subjects with GERD who have persistent symptoms while on PPI therapy.
Conditions Studied
Interventions
- DRUG SSP-002358 (0.1 mg) + PPI
- DRUG SSP-002358 (0.5 mg) + PPI
- DRUG SSP-002358 (2.0 mg) + PPI
- DRUG Placebo + PPI
Study Locations (20)
Florida
- Medical Research Unlimited, LLC - Aventura
- Consultants for Clinical Research of South Florida - Boynton Beach
- PAB Clinical Research - Brandon
- Avail Clinical Research, LLC - DeLand
- S & W Clinical Research - Fort Lauderdale
- Medical Research Unlimited, LLC - Hialeah
- Jupiter Research - Jupiter
- Pines Clinical Research, Inc. - Pembroke Pines
- Radiant Research - Pinellas Park
Arkansas
- Lynn Institute of the Ozarks - Little Rock
- Preferred Research Partners, Inc - Little Rock
- Arkansas Gastroenterology - North Little Rock
California
- Anaheim Clinical Trials - Anaheim
- Southern California Research Institute Medical Group Inc - Los Angeles
- Medical Center for Clinical Research - San Diego
Arizona
- HOPE Research Institute - Phoenix
- Genova Clinical Research - Tucson
Connecticut
- Connecticut Gastroenterology Institute - Bristol
- Stamford Therapeutics Consortium - Stamford
Colorado
- Clinicos - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2012-02-27 |
| Est. Completion | 2013-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01472939
The ClinicalTrials.gov registry entry for NCT01472939 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 328-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (46% higher). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 4 interventions - of which SSP-002358 (0.1 mg) + PPI is the first listed.
NCT01472939 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT01472939 about?
NCT01472939 is a clinical study titled "Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)". The aim of this study is to establish a dose-related effect of a selective 5-HT4 receptor agonist compared to placebo on residual symptoms (regurgitation with or without heartburn) in subjects with GERD who have persistent symptoms while on PPI therapy.
What is the current status of trial NCT01472939?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2012-02-27. Estimated completion is 2013-05-14.
What conditions does trial NCT01472939 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux Disease.
What interventions are being tested in trial NCT01472939?
The interventions under investigation include: SSP-002358 (0.1 mg) + PPI (DRUG), SSP-002358 (0.5 mg) + PPI (DRUG), SSP-002358 (2.0 mg) + PPI (DRUG), Placebo + PPI (DRUG).
Who is sponsoring clinical trial NCT01472939?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01472939 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
COMPLETED · Phase 2
-
A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
COMPLETED · Phase 2
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
COMPLETED · Phase 2
-
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Maintenance Intermittent Therapy for Symptomatic GERD Patients
COMPLETED · Phase 2
-
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.